I.V. acetaminophen is gaining increasing use in children 1 -4 and neonates 1 5 6 despite limited data concerning the pharmacokinetics of this formulation. Population pharmacokinetics of the i.v. prodrug (propacetamol) have been studied in neonates after single 7 8 and repeat administration. 9 There are limited neonatal i.v. acetaminophen pharmacokinetic data available for comparison with the prodrug pharmacokinetics in neonates; attributable in part to its off-label use in children weighing ,10 kg. 5 Dosing regimens used in some institutions for neonates have been published, 5 10 but there are no data validating these regimens. A case report concerning a 4-day-old 3.4-kg term neonate given i.v. acetaminophen 10 mg kg 21 4-hourly for 48 h after bowel surgery documents a trough concentration of 10 mg litre 21 between the fifth and sixth dose, 6 supportive of clearance (CL) estimates. CL determines maintenance dose and increases with postmenstrual age (PMA). The CL estimates from i.v. propacetamol data are 5 . Licensing imposes no weight restriction in Australia, but the Australian product information for i.v. acetaminophen 12 does not consider the CL maturation with age in neonates in its dosing recommendations. The same dose of 15 mg kg 21 6-hourly is suggested for neonates more than 10 days of age and for infants and children up to 33 kg. A reduced dose of 7.5 mg kg 21 6-hourly is proposed in term neonates,10 days of age. 12 Prescribing rights for i.v. acetaminophen were initially restricted to pain service practitioners in our institution. 1 Therapeutic drug monitoring was initiated after the introduction of this drug into neonatal unit (NNU) and broadening of prescribing rights to neonatologists. Analgesic serum concentrations for acetaminophen in neonates are unknown, but an effect site target concentration of 10 mg litre 21 is proposed in children after tonsillectomy. 13 We investigated i.v. acetaminophen pharmacokinetics after repeat dosing in neonates in the NNU. We wished to observe serum time -acetaminophen concentration profiles, investigate covariate effects on pharmacokinetics, to assess hepatic safety through liver transaminase enzyme testing and to revise dosing regimens in response to CL estimates.
Methods
This study was approved by the Ethics in Human Research Committee (EHRC) and performed in neonates nursed in the NNU at a tertiary paediatric centre. Parents of neonates were provided with written and verbal information and approached for written consent once their neonate had received at least two doses and required further i. . This dosing regimen was calculated at 15% less than the current oral dosing regimen used within the NNU.
Blood samples (venous, arterial, or skin capillary) for acetaminophen assay were obtained and a daily liver function test (LFT) was performed opportunistically when other routine blood samples were obtained after enrolment into the study. Times for this sampling were not fixed. Volume of these additional samples was limited to ,0.5 ml per patient, with a maximum of five samples per neonate. An EHRC requirement was to assay the samples in series (rather than batch analysis after storage at 2208C) to allow for individual patient dose adjustment in response to a trough concentration of .40 mg litre 21 or LFT changes. The LFT panel included bilirubin (conjugated and unconjugated), alanine aminotransferase (ALT), gamma-glutamyl transaminase (GGT), alkaline phosphatase (ALP), albumin, and total protein. Where serum volumes were small, unconjugated bilirubin, albumin, and ALT were assayed preferentially. Doubling of ALT was predefined as a marker of possible hepatotoxicity. Abnormal LFT concentrations were defined using the Pharmacokinetic analysis Population parameter estimations. A one-compartment linear disposition model with first-order elimination was used to analyse time-concentration profiles. Population parameter estimates were obtained using non-linear mixed effects modelling (NONMEM). 14 This modelling accounts for population parameter variability (PPV, between and within subjects) and residual variability (random effects) and parameter differences predicted by covariates (fixed effects). The PPV in model parameters was modelled by a proportional variance model. A proportional term characterized the residual unknown variability. The population mean parameters, between subject and residual variances, were estimated using the first-order conditional interaction estimate method using ADVAN1 TRANS2 of NONMEM V. Convergence criterion was determined up to three significant digits. A Compaq Digital Fortran Version 6.6A compiler with Intel Celeron 333 MHz CPU (Intel Corp., Santa Clara, CA, USA) under MS Windows XP (Microsoft Corp., Seattle, WA, USA) was used to compile NONMEM.
The PPV is modelled in terms of random effect (h) variables. Each of these variables is assumed to have mean 0 and a variance denoted by v 2 , which is estimated. The covariance between the two elements of h, for example, CL and V are a measure of statistical association between these two variables. Their covariance is related to their correlation (R), for example,
The covariance of CL and distribution volume (V) variability was incorporated into the model.
Covariate analysis.
The parameter values were standardized for a body weight of 70 kg using an allometric model.
where P i is the parameter in the ith individual, W i is the weight in the ith individual, and P std is the parameter in an individual with a weight W std of 70 kg. This standardization allows the comparison of neonatal parameter estimates with those reported for adults. The PWR exponent was 0.75 for CL, 0.25 for half-times, and 1 for V.
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Exploration of a relationship between CL and unconjugated bilirubin (unbili) was explored using a slope parameter (SLP unbili ).
Covariate analysis included a model investigating age-related changes in CL and V using linear function:
where V std and CL std are the population estimates for V and CL, respectively, standardized to a 70 kg person using allometric models; PMA (weeks) is the postmenstrual age; PNA (weeks) is postnatal age; SLP V and SLP CL are constants describing age-related changes in V and CL, referenced to 40 weeks PMA or birth (PNA=0). The quality-of-fit of the pharmacokinetic model to the data was sought by NONMEM's objective function and by visual examination of plots of observed vs predicted concentrations. Bootstrap methods 16 provided a method to evaluate parameter uncertainty. Models were nested and an improvement in the objective function was referred to the Chisquared distribution to assess the significance [e.g. an objective function change (OBJ) of 3.84 is significant at a=0.05].
Simulation. A simulation study was performed using NONMEM software to investigate the acetaminophen concentration variability after a standard dose of i.v. acetaminophen 15 mg kg 21 6 hourly in neonates of 34-44 weeks PMA. The drug was infused over 20 min. Simulated neonates (n=1000) were aged 39.4 (SD 2.88) weeks PMA with a weight 2.99 (0.66) kg (range: 1.2-4.5 kg). Pharmacokinetic parameter estimates and their variability from this current study were used to predict the individual time-concentration profiles.
Simulation was also used to investigate the steady-state concentrations after repeat doses in a term neonate. Two dose regimens were explored (7.5 and 15 mg kg 21 given 6 hourly). Mean time -concentration profiles were performed using Berkeley Madonna TM modelling and analysis of dynamic systems software (R. Macey and G. Oster, University of California, Berkeley, CA, USA).
Results
There were 50 neonates enrolled into the study. Most received i.v. acetaminophen for postoperative pain for 1 -9 days. Table 1 lists patient characteristics, the number of doses received and if the dose given was correct for patients' PMA, therapy duration and indication for i.v. acetaminophen, other parenteral therapies and the number of acetaminophen assays performed. There were 189 acetaminophen serum concentration observations available for pharmacokinetic analysis. The median (range) value obtained was 17 (,6 -50) mg litre 21 taken a median of 3.5 h after the preceding dose, after a median (range) of 5 (2-17) prior doses. There were 147 concentrations (81%) above 10 mg litre
21
; 17 (9%) were ,6 mg litre 21 , which occurred in 13 neonates a median of 10.1 h after dose. These reflect trough values in the setting of a median (range) of 4 (2 -17) prior doses.
Population parameter estimates are listed in Table 2 . Individual concentration predictions are based on values of maximum a posteriori Bayesian estimates of the parameters using the post hoc option, whereas predicted typical ( population) concentrations are based on population parameters and covariate information. The correlation between subject variability for CL and V was 0.39. CL increased with increasing PMA: from 4. (Fig. 1, Table 3 ). There was no relationship between V and PMA or PNA.
There were 14 patients with pre-existing unconjugated hyperbilirubinaemia (Table 4) . CL was reduced in the presence of unconjugated hyperbilirubinaemia; a concentration of 150 mmol litre 21 was associated with 40% reduction in CL (Fig. 2) . Figure 3 shows concentration variability after a standard dose of i.v. acetaminophen 15 mg kg 21 6 hourly in neonates of 34 -44 weeks PMA. Figure 4 demonstrates the two predicted time -concentration profiles obtained with regular 6 h dosing of 7.5 and 15 mg kg 21 for a 40-week PMA neonate. Steady-state concentrations are achieved after three doses with a trough concentration of 10 mg litre 21 and a peak concentration of 23 mg litre 21 after regular dosing with 15 mg kg
. The lower dose (7.5 mg kg
) achieved half of these concentrations. Fifty patients had a mean of 4.6 LFTs performed (range: 2 -8) with 231 available for an assessment, of which 84% were complete, 6% were partial panels, and 10% had only unconjugated and total bilirubin performed. At least one full panel was available for all 50 patients, while 30 patients (60%) had complete panels for all LFT assessments. For 23 patients, there was a baseline LFT set before commencement of i.v. acetaminophen and, for the remainder, the first set was taken on the day of the first acetaminophen assay. Table 4 lists the LFT findings and abnormal values for neonates according to PNA; the day-to-day changes in ALT, GGT, ALP, and unconjugated bilirubin for all patients are presented graphically in Figure 5 . The lowess curve is below the normal values and flat (indicating no change for the majority) for ALT, GGT, and ALP for 48 h before through to 192 h after Multidose i.v. acetaminophen pharmacokinetics in neonates these patients was a premature 2.2 kg neonate (PMA 35 weeks, PNA 11 days) with an unconjugated hyperbilirubinemia and a congenital diaphragmatic hernia whose baseline ALT was high and remained elevated (125, 144, 114 U litre
). Another near term 3.3 kg neonate (PNA 37 days) with imperforate anus and rectovaginal fistula had an elevated baseline ALT (128 U litre
) that decreased to normal. The third was a term 3.7 kg neonate (PNA 7 days) post-laparotomy for necrotizing enterocolitis whose ALT was mildly elevated (88 U litre 
Discussion
This is the first study to investigate pharmacokinetics after multiple doses of i.v. acetaminophen in term and preterm neonates, administered according to a PMA-adjusted dosing regimen. The estimate for CL ( ). 8 9 We were able to demonstrate CL maturation with PMA. There were only 11 premature neonates in this current analysis, but population CL estimates are similar to those reported for propacetamol. 8 The volume of distribution decreases with PNA, 8 17 18 but we were unable to reveal this trend in this current neonatal cohort. Dosing regimens for i.v. acetaminophen 5 10 are based on the CL estimates from propacetamol data, and it is reassuring to note similar estimates for the i.v. acetaminophen formulation.
Measurement of unconjugated bilirubin concentration is a crude measure of hepatic conjugating ability. Both bilirubin and acetaminophen are cleared by glucuronosyltransferase; bilirubin by UGT1A1 and acetaminophen by UGT1A6. Acetaminophen is metabolized in neonates by both sulphate and glucuronide conjugation. Glucuronide:sulphate ratios range from 0.12 in premature neonates of 28-32 weeks postconception, 19 0.28 in those at 32-36 weeks postconception, 19 and 0.34 in term neonates of 0-2 days old.
20
Bilirubin is also conjugated with glucuronide and increased unconjugated bilirubin may reflect immaturity of this process. Alternatively, increased unconjugated bilirubin may reflect increased bilirubin production. Increased unconjugated bilirubin concentration is a late sign of reduced CL; CL will be reduced before this marker is elevated, in the first few days of life (Fig. 5) . CL is related more closely to PMA than PNA, 15 rendering PNA a poor marker of conjugating ability. We therefore suggest that the dosing recommendations not be exceeded in the first few days of life and that acetaminophen dose be reduced in the presence of unconjugated hyperbilirubinaemia. Observed serum acetaminophen concentrations after multi-dosing in this patient population are generally above the target serum concentration of 10 mg litre 21 after a median of three doses. Simulation (Fig. 4) demonstrates that mean concentrations above 10 mg litre 21 are achieved in term neonates after 15 mg kg 21 6-hourly, but not after the lower dose of 7.5 mg kg 21 . In Europe, a loading dose of 20 mg kg 21 , independent of PMA, is recommended. 5 10 This will achieve a higher initial peak serum concentration and earlier steady state with continued dosing, but the target concentration for analgesia is not established for neonates and the efficacy of this practice has not yet been assessed. A concentration-analgesic response relationship has only been described for tonsillectomy pain in children. 13 The pain insults suffered by neonates in a NNU are different from tonsillectomy, and neuronal pathways transmitting or modulating pain are developing in neonates. 21 Repeat administration of what was considered routine doses (75-90 mg kg 21 day
21
) of acetaminophen can cause hepatotoxicity in children 22 through production of highly reactive electrophilic arylating metabolites [e.g. N-acetylp-benzoquinone-imine (NAPQI)] by the hepatic cytochrome P-450-dependent mixed function oxidase enzyme system. Hepatotoxicity is dependent on the balance between the rate of NAPQI formation, the capacity of the safe elimination pathways of sulphate and glucuronide production, and the initial content and maximal rate of synthesis of hepatic glutathione. The balance of these factors in term and preterm neonates remains unknown. Neonates have been reported to have high serum acetaminophen concentrations after intentional maternal overdose prepartum. 23 . The patient had an unconjugated bilirubin at the high end of the normal range at 130 mmol litre 21 with an elevated conjugated bilirubin of 25 mmol litre 21 with a marked liver derangement on admission and recovered fully after receiving N-acetyl cysteine for more than 7 days. 25 Acetaminophen concentrations associated with increased NAPQI are not reported in neonates and the activity of CYP2E1, the major enzyme producing NAPQI, is unquantified, but thought to be reduced. 26 Consequently, it is currently difficult to predict 'safe' doses in this subpopulation.
There is no simple test to assess for potential hepatotoxicity. Kozer and colleagues 27 have demonstrated that ill children receiving repeated large doses of acetaminophen (.90 mg kg 21 day
) may show abnormalities in liver function. Previous adult studies have shown that ALT changes during long-term (1 -12 month) chronic dosing for osteoarthritis are mild and resolve, 28 while recently ALT elevations (.3Â normal) were documented more commonly in volunteers after 1 week of treatment with acetaminophen with or without opioids, while all placebo receivers had normal ALTs or ALTs remaining below 1 -3 times normal. 29 Liver function was monitored in this neonatal cohort also by measuring ALT enzyme changes; all patients were nil by mouth, the majority co-receiving TPN. The one patient whose ALT rose significantly to three times normal (as seen in healthy adults) had renal impairment. This neonate also had low birth weight and was fasting perioperatively without TPN supplementation. His bilirubin was normal and his acetaminophen CL was within the neonatal range. His ALT rose in isolation and no conclusions can be drawn about the contribution of acetaminophen or coexisting pathology to the ALT changes seen.
I.V. acetaminophen is an attractive analgesic for neonatal use in the postoperative period and for those with restricted oral intake. It offers an alternative or supplement to opioid analgesia in term or preterm patients in whom the reduction of opioid associated side effects is frequently desirable. This study affirms serum concentrations after a PMA-based dosing regimen, which will continue to be used in our NNU. Serum unconjugated bilirubin concentration serves as a marker of reduced CL. 
